Drugmaker pays $442m voguish Plavix patent case
BMY and Sanofi SA further than $442 million to aim a decade-long patent infringement casing more than blockbuster blood thinner Plavix, the worlds second-best-selling drug. Apotex Corp., Canadas biggest drugmaker, has paid the two brand-name drugmakers $442.2 million at home compensation intended for advertising a generic version of Plavix at home 2006. Apotex launched its copycat version while it was still participating in a quad dispute with Bristol and Sanofi, partners who jointly souk Plavix. Apotex argued by the count to vital patents on Plavix were void, responsibility whats called an at-risk launch of its generic version of Plavix.